arct-2138
Gene therapyexperimental
Clinical trial activity
1 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Dec 31, 2023 (NCT06125691)
Timeline
2020s
- Jan 1, 2023
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Ornithine decarboxylaseSupplementation
ODC1 supplementation
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06125691 | Phase 1 | Dec 31, 2023 | Arcturus Therapeutics, CSL Behring, Novotech |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Arcturus Therapeutics | For profit | 1 | 1 | 1 | 2023 |
| CSL Behring | For profit | 1 | 0 | 1 | 2023 |
| Novotech | For profit | 1 | 0 | 1 | 2023 |
3 organizations
Page 1 / 1